Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)

The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alteratio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Sakai, Kazuko, Takahama, Takayuki, Shimokawa, Mototsugu, Azuma, Koichi, Takeda, Masayuki, Kato, Terufumi, Daga, Haruko, Okamoto, Isamu, Akamatsu, Hiroaki, Teraoka, Shunsuke, Ono, Akira, Ohira, Tatsuo, Yokoyama, Toshihide, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko, Nishio, Kazuto
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782093/
https://ncbi.nlm.nih.gov/pubmed/33131198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12841
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados